Jubilant Generics will make the drug available to over 1,000 hospitals providing Covid-19 treatment in India through its distribution network, the company said in a release. Jubilant had entered into a non-exclusive licensing agreement with US Gilead Sciences, Inc. In May, which that granted it the right to register, manufacture and sell Gilead’s investigational drug Remdesivir in 127 countries including India.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3i421aK
via IFTTT
0 comments:
Post a Comment